Sarkozy, C., Hawkes, E. A., Song, Y., Ozcan, M., Morschhauser, F., Andreadis, C., Akyol, A., Rao, P., Micco, A. D., Petel, A., Perna, S. K., Herrera, A. F. (2026). Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps7102